Biofrontera AG

  • WKN: 604611
  • ISIN: DE0006046113
  • Land: Deutschland

Nachricht vom 14.01.2020 | 06:30

Biofrontera AG: Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck

DGAP-News: Biofrontera AG / Key word(s): Study results/Miscellaneous
14.01.2020 / 06:30
The issuer is solely responsible for the content of this announcement.

Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck

Leverkusen, Germany, January 14, 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced follow-up results for its Phase III clinical study evaluating the safety and efficacy of photodynamic therapy (PDT) with Ameluz(R) and the BF-RhodoLED(R) lamp for the treatment of actinic keratosis (AK) on the extremities, trunk and neck. After 12 months, the overall lesion recurrence rates were 14.1% after Ameluz(R) treatment, compared to 27.4% after placebo treatment in the Full Analysis Set (FAS; 11.7% vs. 24.6% in the Per Protocol Set, respectively).

"I am not aware of another pivotal clinical study showing similarly high clearance rates and low recurrence rates for the pharmaceutical treatment of actinic keratoses in the periphery," commented Biofrontera's CEO Prof. Hermann Luebbert. "With an overall lesion clearance rate of 77% one year after treatment, Ameluz(R) has once again demonstrated its unreached clinical efficacy."

The multi-center, randomized, double-blind, intra-individual study included 50 patients at six study sites in Germany, each with four to ten clinically confirmed AK lesions in comparable areas on the right and left side of the extremities and/or trunk/neck. Mild, moderate and severe actinic keratoses were treated with one or, if at least one lesion on each patient's side persisted after three months, two PDT applications. Each PDT consisted of the application of Ameluz(R) on one side of the patient, and an identically looking, feeling and smelling placebo gel on the other side. PDT illumination with 10 minutes of red light using the BF-RhodoLED(R) lamp followed after a 3-hour incubation with occlusion. The final examination of the patients took place three months after the last PDT. This clinical study phase was followed by a follow-up phase of up to one year after the last PDT, in which recurrence rates and numbers of new AKs and skin tumors were determined.

The results for the primary regulatory endpoint, demonstrating that Ameluz(R) was superior (p<0.0001) to placebo based on its mean total lesion clearance rate of 86% compared to 33% for placebo had been published in a Biofrontera press release on March 20, 2019.

The following table represents the treatment outcome after 3 months and the recurrence rates during one year after the last PDT (FAS).

Endpoints (all FAS) Ameluz(R)

Fully cleared lesions after 3 months
Placebo

Fully cleared lesions after 3 months
Ameluz(R)

12-month recurrence
Placebo

12-month recurrence
Lesions per patients' side (overall) 86.0% 32.9% 14.1% 27.4%
Lesions per patients' side - extremities 83.5% 27.1% 16.2% 34.3%
Lesions per patients' side - neck/trunk 96.0% 55.5% 6.7% 10.7%
Mild lesions per patients' side (overall) 88.3% 37.3% 14.0% 39.2%
Moderate lesions per patients' side (overall) 84.3% 27.2% 11.6% 18.6%
Severe lesions per patients' side (overall) 71.4% 42.9% 20.0% 66.7%

Of the patients who were cleared of all AK lesions 3 months after treatment (67.3%), 62.5% overall and 60.9% of the patients treated on extremities (placebo 66.7% and 66.7%, respectively) remained fully cleared up to one year after the last PDT. No new AKs and only one basal cell carcinoma (BCC) skin tumor were identified in the treatment area after one year whereas outside the treatment area 6 AKs or skin tumors (BCC, squamous cell carcinoma) where identified.

-End-
 

Enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer


+49 (0) 214 87 63 2 0
ir@biofrontera.com
IR UK: Seton Services
Toni Vallen

+44(0) 20 7729 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592


About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi(TM) for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.



14.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

amalphi AG

Original-Research: amalphi AG (von Sphene Capital GmbH): Buy

25. September 2020